For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Research and development expenses | 432,530 | 521,069 | 732,315 | - |
| General and administrative expenses | 1,568,951 | 1,243,009 | 1,150,397 | - |
| Total operating expenses | 2,001,481 | 1,764,078 | 1,882,712 | - |
| Loss from operations | -2,001,481 | -1,764,078 | -1,882,712 | -2,267,293 |
| Other income (expenses) | - | -513 | -861 | - |
| Interest income | 47,059 | 47,860 | 23,747 | - |
| Losses from equity method investment | -67,970 | -76,920 | -98,730 | - |
| Inducement expense | - | - | 0 | - |
| Total other income (expense) | -20,911 | -29,573 | -75,844 | - |
| Net loss | -2,022,392 | -1,793,651 | -1,958,556 | -2,228,801 |
| Basic EPS | -1.48 | -0.08 | -0.18 | -0.34 |
| Diluted EPS | -1.48 | -0.08 | -0.18 | -0.34 |
| Basic Average Shares | 1,370,109 | 22,171,309 | - | - |
| Diluted Average Shares | 1,370,109 | 22,171,309 | 10,622,720 | 6,539,760 |
ADIAL PHARMACEUTICALS, INC. (ADIL)
ADIAL PHARMACEUTICALS, INC. (ADIL)